Ipswich Investment Management Co. Inc. cut its holdings in Crispr Therapeutics AG (NASDAQ:CRSP) by 4.8% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 38,965 shares of the company’s stock after selling 1,950 shares during the period. Ipswich Investment Management Co. Inc. owned approximately 0.06% of Crispr Therapeutics worth $2,864,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds have also bought and sold shares of the company. State Street Corp raised its position in shares of Crispr Therapeutics by 48.2% in the 1st quarter. State Street Corp now owns 71,211 shares of the company’s stock worth $3,020,000 after acquiring an additional 23,159 shares in the last quarter. Royal Bank of Canada raised its position in shares of Crispr Therapeutics by 5.9% in the 1st quarter. Royal Bank of Canada now owns 114,657 shares of the company’s stock worth $4,863,000 after acquiring an additional 6,420 shares in the last quarter. Morgan Stanley increased its position in Crispr Therapeutics by 233.6% in the 1st quarter. Morgan Stanley now owns 851,519 shares of the company’s stock valued at $36,113,000 after buying an additional 596,255 shares in the last quarter. Clearbridge Investments LLC increased its holdings in Crispr Therapeutics by 45.7% during the 1st quarter. Clearbridge Investments LLC now owns 6,700 shares of the company’s stock worth $284,000 after purchasing an additional 2,100 shares in the last quarter. Finally, HighTower Advisors LLC increased its holdings in Crispr Therapeutics by 9.9% during the 1st quarter. HighTower Advisors LLC now owns 20,550 shares of the company’s stock worth $873,000 after purchasing an additional 1,850 shares in the last quarter. 57.97% of the stock is owned by hedge funds and other institutional investors.
CRSP traded up $0.64 during trading on Thursday, reaching $94.81. The stock had a trading volume of 126,144 shares, compared to its average volume of 1,224,713. The stock has a market cap of $5.66 billion, a PE ratio of 125.56 and a beta of 2.35. Crispr Therapeutics AG has a one year low of $32.30 and a one year high of $97.82. The business has a 50-day moving average of $68.99 and a 200-day moving average of $56.79.
Crispr Therapeutics (NASDAQ:CRSP) last released its earnings results on Tuesday, April 28th. The company reported ($1.15) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.05) by ($0.10). Crispr Therapeutics had a net margin of 15.73% and a return on equity of 6.54%. The firm had revenue of $0.16 million during the quarter, compared to the consensus estimate of $3.04 million. During the same period in the prior year, the company earned ($0.93) EPS. The firm’s revenue was down 52.1% compared to the same quarter last year. On average, analysts forecast that Crispr Therapeutics AG will post -4.57 earnings per share for the current fiscal year.
In other Crispr Therapeutics news, COO Lawrence Otto Klein sold 65,088 shares of the firm’s stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $75.93, for a total value of $4,942,131.84. Following the completion of the sale, the chief operating officer now directly owns 58,666 shares in the company, valued at $4,454,509.38. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Bradley J. Phd Bolzon sold 20,000 shares of the firm’s stock in a transaction dated Monday, July 6th. The stock was sold at an average price of $82.39, for a total transaction of $1,647,800.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 265,214 shares of company stock valued at $18,931,054. 21.40% of the stock is currently owned by company insiders.
A number of brokerages have commented on CRSP. BidaskClub raised Crispr Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday. Zacks Investment Research downgraded Crispr Therapeutics from a “buy” rating to a “hold” rating and set a $56.00 target price on the stock. in a research note on Friday, April 24th. William Blair restated a “buy” rating on shares of Crispr Therapeutics in a research note on Tuesday, April 28th. Oppenheimer boosted their target price on Crispr Therapeutics from $80.00 to $89.00 and gave the stock an “outperform” rating in a research note on Tuesday, June 23rd. Finally, Roth Capital boosted their target price on Crispr Therapeutics from $100.00 to $105.00 and gave the stock a “buy” rating in a research note on Friday, June 19th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the stock. Crispr Therapeutics currently has an average rating of “Buy” and an average target price of $74.39.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
See Also: Terms to Better Understand Call Options
Want to see what other hedge funds are holding CRSP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Crispr Therapeutics AG (NASDAQ:CRSP).
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.